Floatz logo

Odetiglucan

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Dana-Farber Cancer Instituteother_biologicalPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

40 Active assets in the Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas cohort.

Asset / SponsorPhaseRating
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fox Chase Cancer Center
Phase 3BB
Pembrolizumab
University of Washington
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase 3BB

View all 50 →

Same molecule, other indications

Odetiglucan is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →